Uveitis Pipeline | Companies – Eli Lilly and Company, Santen Inc, Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology
DelveInsight’s, “Uveitis Pipeline Insight 2023” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Uveitis pipeline landscape. It covers the Uveitis pipeline drug profiles, including Uveitis clinical trials and nonclinical stage products. It also covers the Uveitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Uveitis Pipeline treatment landscape of the report, click here @ Uveitis Pipeline Outlook
Key Takeaways from the Uveitis Pipeline Report
- DelveInsight’s Uveitis Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Uveitis.
- The leading Uveitis Companies include Eli Lilly and Company, Santen Inc, Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and Others.
- Promising Uveitis Pipeline Therapies include Barcitinib, EYS606, Adalimumab, Prednisone, Fluocinolone Acetonide Intravitreal Implant 0.18 mg, QLETLI, Prednisone, Dexamethasone, and others
- RG6179 (RO720220) is a nonsteroidal drug to improve vision in people with uveitis macular edema. It is administered through the intravitreal route and is a potent blocker of free IL-6, and IL-6 complexed to the soluble IL-6 receptor (IL-6R). Currently, it is being investigated in two Phase III trials, and this study aims to assess the safety and efficacy of RO720220 in participants with uveitis macular edema.
- Baricitinib (Eli Lilly and Company): It is a Janus kinase selective inhibitor that works by interfering with cytokine signaling to influence immune cell function and inflammation by reducing phosphorylation and activating signal transducers and activators of transcription. It is currently being developed in the Phase III trial initiated in patients with active JIA-associated uveitis or chronic anterior antinuclear antibody-positive uveitis.
- OCS-02 (Oculis): OCS-02 is a single-chain antibody fragment that binds to and neutralizes the activity of human TNFα. Based on the dual mechanism of action, including anti-inflammatory and anti-necrosis properties, the company anticipated initiating Phase IIb clinical trials in the first half of 2023, evaluating its use as a potential treatment for noninfectious anterior uveitis.
- Izokibep (Acelyrin/Affibody Medical): ABY-035 is a small therapeutic protein inhibitor of interleukin-17A (IL-17A) designed to overcome the limitations of monoclonal antibodies. It is being developed for treating posterior uveitis, pan uveitis, noninfectious uveitis, and intermediate uveitis. Izokibep can reach high drug exposure levels through a single SC injection due to its small molecular size. Currently, it is being investigated in Phase IIb for noninfectious uveitis.
For further information, refer to the detailed Uveitis Unmet Needs, Uveitis Market Drivers, and Uveitis Market Barriers, click here for Uveitis Ongoing Clinical Trial Analysis
Uveitis Overview
Uveitis is a general term describing a group of inflammatory diseases that produces swelling and destroys eye tissues. These diseases can slightly reduce vision or lead to severe vision loss. Uveitis is swelling of the middle layer of the eye, which is called the uvea. It may occur from both infectious and non-infectious causes. Uveitis is caused by inflammatory responses inside the eye. Inflammation is the body’s natural response to tissue damage, germs, or toxins.
Uveitis Emerging Drugs
- Barcitinib: Eli Lilly and Company
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling. Eli Lilly and Company is conducting a Phase III clinical trial to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.
- EYS606: Eyevensys
EYS606 is a novel non-viral gene therapy approach being developed for the treatment of chronic non-infectious uveitis (CNIU) is being evaluated in Phase II stage of development. EYS606 combines plasmids encoding a potent fusion protein that neutralizes the activity of TNF-α and the proprietary Eyevensys Electrotransfection System used to introduce the plasmids into the eye. TNF is a cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in CNIU. EYS606 has already received orphan designation in Europe and is being investigated in 2 ongoing clinical trials enrolling patients with CNIU.
Request a sample and discover the recent advances in Uveitis Ongoing Clinical Trial Analysis and Medications, click here @ Uveitis Treatment Landscape
Uveitis Pipeline Therapeutics Assessment
There are approx. 15+ key companies are developing therapies for Uveitis. The companies which have their Uveitis drug candidates in the most advanced stage, i.e. Phase III include Eli Lilly and Company.
Dive deep into rich insights for drugs for Uveitis Market Drivers and Uveitis Market Barriers, click here @ Uveitis Unmet Needs and Analyst Views
Scope of the Uveitis Pipeline Report
- Coverage- Global
- Uveitis Companies- Eli Lilly and Company, Santen Inc, Clearside Biomedical, Affibody, Eyevensys, Alcon Research, Panoptes Pharma GmbH, Tarsier Pharma, Eye Pharma, Apitope Technology, Mitotech, and Others.
- Uveitis Pipeline Therapies- Barcitinib, EYS606, Adalimumab, Prednisone, Fluocinolone Acetonide Intravitreal Implant 0.18 mg, QLETLI, Prednisone, Dexamethasone, and others.
- Uveitis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Uveitis Mergers and acquisitions, Uveitis Licensing Activities @ Uveitis Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Executive Summary
- Uveitis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Phase III)
- Baricitinib: Eli Lilly and Company
- Drug profiles in the detailed report…..
- Mid-Stage Products (Phase II)
- EYS606: Eyevensys
- Drug profiles in the detailed report…..
- Early-stage products (Phase I/II)
- TRS01: Tarius Pharma
- Drug profiles in the detailed report…..
- Inactive Products
- Uveitis Key Companies
- Uveitis Key Products
- Uveitis- Unmet Needs
- Uveitis- Market Drivers and Barriers
- Uveitis- Future Perspectives and Conclusion
- Uveitis Analyst Views
- Uveitis Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
